Leader Biomedical and Urogyn collaborate to bring innovative new procedure Urolastic™ to India

10 January 2017- Amsterdam, The Netherlands- Urogyn B.V. and Leader Biomedical are proud to announce that Urolastic™ - an innovative Urinary Stress incontinence product - has been introduced into the product registration process in India. This marks the first step towards bringing a novel therapeutic solution to patients and caregivers in India.

Many women suffer from Stress Urinary Incontinence (SUI), radically affecting their quality of life due to restraining problems. Their social life is negatively influenced by involuntary leakage during coughing, sneezing, laughing or exercise. Urogyn has developed a product that shares the properties of being injectable, but does not shrink or degrade, thus remaining effective in the longer term. The material will also show up on X-rays and ultrasound, and can be removed if required.

Urolastic™ is an extremely biocompatible rubbery compound that forms in place after injection. The product consists of a dual syringe that is connected to a static mixing tube with a needle. When the dual syringe is compressed, the two components meet and mix in the static mixing tube. The mixed compound is then passed through the needle. This permits small amounts of compound to be placed in the tissue around the urethra. The mixture forms as small flexible balls, which are over time encapsulated in scar tissue.

“Urogyn B.V. has developed a unique, innovative, cost effective, and above all, female friendly procedure for the treatment of urinary incontinence in women. Our product Urolastic™ provides a minimally-invasive treatment, which is performed under local anesthesia and delivers long-lasting improvements to the quality of life of the patient. Through our new partnership with Leader Biomedical we are able to bring this state of the art treatment for Urinary Stress incontinence to the Indian market.” says Martijn Ligtenberg, COO/CFO, Urogyn B.V.

“The collaboration with Urogyn allows us to further increase our downstream value chain and supports our vision to continuously improve global access to next generation healthcare to India. We see great promise for this product here and we are diligently evaluating opportunities to carry the product in the Leader Biomedical network globally. As part of this larger goal, the product is expected to be introduced in India in the lag end of FY 2017”, adds Basil Babychan, Business Director, Leader Biomedical Group.

About Urogyn:
Urogyn was founded in 2009 with the ambition of developing new products in the field of urology and gynaecology, based upon a two-component polymer technology. The first products are now used in the treatment of Stress Urinary Incontinence (SUI) for both men and women. More products are expected to be commercially launched in the near future for birth control and treating faecal incontinence (www.urogynbv.com).

About Leader Biomedical:
Leader Biomedical seeks to become a leader in the supply of biomaterials and surgical implants, improving global markets’ access to next generation technologies, and medical devices (www.leaderbiomedical.com).

Leader Biomedical Europe B.V.
Herikerbergweg 300 | Diana Building
1101 CT Amsterdam
The Netherlands

This release was published on openPR.